Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.
CONCLUSION: Combined elevation of TRIB2 and MAP3K1 could be novel prognostic biomarkers and potential therapeutic targets to evaluate the malignancy and long-term outcomes of GBM. PMID: 31318172 [PubMed - as supplied by publisher]
CONCLUSIONS: NEO100 could have significant value targeting GSCs and could be used for GBM therapy as either monotherapy or a coadjuvant therapy during temozolomide rest cycles. PMID: 31419797 [PubMed - as supplied by publisher]
CONCLUSIONS: Resection of M1 tumors is feasible and safe. By adapting the stimulation paradigm and probe appropriately to the clinical context, the best resection and functional results can be achieved. PMID: 31398706 [PubMed - as supplied by publisher]
Conditions: Glioblastoma; Medulloblastoma; Ependymoma; Diffuse Intrinsic Pontine Glioma Interventions: Drug: Indoximod; Radiation: Partial Radiation; Radiation: Full-dose Radiation; Drug: Temozolomide; Drug: Cyclophosphamide; Drug: Etoposide; Drug: Lomustine Sponsors: Theodore S. Johnson; Emory University Not yet recruiting
Conclusion: Our results suggest that an adjuvant treatment of glioma patients with ML-containing drugs might be beneficial. PMID: 31354846 [PubMed]
In this study, we explored the roles of the FREM2 and SPRY1 genes and their proteins in glioblastoma pathology using human tissue samples. We used proteomic, transcriptomic, and bioinformatics approaches to detect changes at different molecular levels. We demonstrate increased FREM2 protein expression levels in glioblastomas compared to reference samples. At the transcriptomic level, both FREM2 and SPRY1 show increased expression in tissue samples of different glioma grades compared to nonmalignant brain tissue. To broaden our experimental findings, we analyzed The Cancer Genome Atlas glioblastoma patient datasets. We disc...
Researchers from the University of Nottingham have developed a new biomaterial that delivers chemotherapies to treat brain cancer. Their work demonstrates that their biodegradable paste led to increased survival compared to controls, and that half of...
Conclusion: The risk signature with 5 genes could serve as an independent factor for predicting the prognosis of patients with GBM. Moreover, the nomogram with the risk signature and clinical traits proved to perform better for predicting 1, 3, 5-year survival rate.
ConclusionsThe CNS penetration observed was encouraging enough to move ribociclib forward with preclinical efficacy studies in models of pediatric brain tumors.